A pilot study of MUC1 vaccine in current and former smokers at high risk for lung cancer
Ended Awarded Last action
- Contract number
- HHSN26100013
- Awardee
-
Mayo Clinic UEI Y2K4F9RPRRG7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $785,458
Award facts
- Opportunity
-
- N01CN0501469 Solicitation number
- Contract value 100% obligated
- $785,458.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Rochester, MN 55905, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $42,852 | |
| Supplemental Agreement for work within scope | $15,640 | |
| Exercise an Option | $336,870 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $390,096 |
Show all 11
About this award
This federal contract was awarded by the National Cancer Institute (NCI) to the Mayo Clinic, a large non-profit academic medical center, to conduct a pilot study of a MUC1 vaccine in current and former smokers at high risk for lung cancer. The $785,458.00 cost-reimbursement contract has a period of performance through March 31, 2023.
Mayo Clinic is serving as the prime contractor and has subcontracted a portion of the work to the University of Pittsburgh, another major research institution. The contract supports the NCI's Cancer Prevention Agent Development Program, which focuses on early-phase clinical research. This award is not associated with a set-aside program. Mayo Clinic has a broader contract vehicle with the NCI, a $9.9 million Indefinite Delivery/Indefinite Quantity contract, which allows the agency to efficiently access the clinic's expertise in cancer research and drug development.
Quick answers
Who was awarded contract HHSN26100013?
HHSN26100013 was awarded to Mayo Clinic by National Cancer Institute (National Institutes of Health) on September 1, 2017.
How much is contract HHSN26100013 worth?
The government has obligated $785,458 on HHSN26100013.
Is contract HHSN26100013 an order under another contract?
Yes. HHSN26100013 is a delivery order under HHSN261201200042I, an indefinite delivery contract.
Was contract HHSN26100013 competed?
The extent of competition for HHSN26100013 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award